The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people affected by Alpha-1 worldwide. Alpha-1 Antitrypsin (Alpha-1) Deficiency is a hereditary condition which may result in serious lung disease in adults and/or liver disease in infants, children and adults. The Foundation has realized continuous growth since its inception in 1995 and has developed a solid infrastructure to promote research and the development of new therapies for improving the quality of life for those diagnosed with Alpha-1. The Foundation has invested more than $76 million to support Alpha-1 Antitrypsin research and programs in 112 institutions in North America, Europe, the Middle East and Australia.